Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

February 21, 2020

First patient dosed with Transgene’s TG6002 in colorectal cancer with liver metastases

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the first patient has successfully received TG6002, via an intrahepatic artery (IHA) infusion, as a locoregional treatment for unresectable liver metastases from colorectal cancer (CRLM).

First patient dosed with Transgene’s TG6002 in colorectal cancer with liver metastases